Atypical Buprenorphine Initiation & Combinations: Using Opioid Affinity to Your Advantage

Current Status
Not Enrolled
Get Started

Case 1: Persistent Naloxone Infusion in an Opioid-Dependent Patient
Case 2: Buprenorphine Precipitated Withdrawal

Release Date: 2/16/2024 

Expiration Date: 2/16/2025

Activity Overview
A Deep Dive into Complex Addiction Cases with Leading Experts! The ACMT Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.

Target Audience
This activity is designed for an audience of Physicians, Nurses, and Pharmacists.

Learning Objectives
Upon completion of the educational activity, participants should be able to:

  • Describe the use of buprenorphine in reducing the need for prolonged naloxone infusion.

Criteria for Success
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. If you have questions about this activity, please contact AKH Inc. at [email protected]

CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.

Ideal Pah Patient Care: New Treatments And Technology Can Improve Patient Outcomes

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

New Injector Immersion Didactic

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit being awarded: 1.25 ANCC contact hours

AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 1.25 contact hours.

Commercial Support
There is no commercial support for this activity.

NameRelationshipCommercial Interest
Gloria J. Baciewicz, MD (Moderator) Addiction Psychiatrist, Strong Recovery Professor of Clinical Psychiatry, Department of Psychiatry, University of Rochester Medical Center, Rochester, NYN/ANothing to disclose
Timothy J. Wiegand, MD, FACMT, DFASAM (Moderator) Director of Toxicology and of the Toxicology Consults University of Rochester Medical Center, Rochester, NY N/ANothing to disclose
Chase Jones, DO, Medical Toxicology Fellow, Lehigh Valley Health Network, Bethlehem, PAN/ANothing to disclose
Joshua Nogar, MD, Attending Physician / Fellowship Director – Medical Toxicology, Northwell Health, Manhasset, NYN/ANothing to disclose
Dorothy Caputo, MA, BSN, RN – VP, Healthcare Continuing Education and Operations AKH Inc., Advancing Knowledge in HealthcareN/ANothing to disclose
Michele Bielarski, RN (planner/reviewer) AKH Inc., Advancing Knowledge in HealthcareN/ANothing to disclose
AKH Inc Staff and PlannersN/ANothing to disclose
ACMT Staff and PlannersN/ANothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships listed for these individuals have been mitigated.

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.